- Conditions
- Lymphoma, Non-Hodgkin, Relapsed Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Lymphoma, B Cell Lymphoma, B-Cell Non-Hodgkin's Lymphoma, Hematologic Malignancy, Relapsed/Refractory Multiple Myeloma, Relapsed/Refractory Acute Myeloid Leukemia
- Interventions
- Caribou-sponsored investigational therapy
- Biological
- Lead sponsor
- Caribou Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2041
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 25 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 3,519
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- NK-Cell Lymphoma, NK-Cell Leukemia, Peripheral T Cell Lymphoma
- Interventions
- Methotrexate, pralatraxate,, Ifosfamide, Dexamethasone, Etoposide, calaspargase pegol, cyclophosphamide, Doxorubicin, Prednisone, Brentuximab Vedotin
- Drug
- Lead sponsor
- New York Medical College
- Other
- Eligibility
- 1 Year to 31 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Orange, California • San Francisco, California + 3 more
- Conditions
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- Interventions
- Axicabtagene Ciloleucel, Platinum-containing Salvage Chemotherapy, Cyclophosphamide, Fludarabine
- Biological · Drug
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 359 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 30
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • La Jolla, California + 24 more
- Conditions
- Central Chondrosarcoma, Grade 2, Central Chondrosarcoma, Grade 3, Dedifferentiated Chondrosarcoma, Metastatic Clear Cell Sarcoma of Soft Tissue, Metastatic Primary Central Chondrosarcoma, Unresectable Primary Central Chondrosarcoma
- Interventions
- Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Gainesville, Florida • Atlanta, Georgia + 7 more
- Conditions
- Ann Arbor Stage II Non-Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma
- Interventions
- Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Prednisone, Rituximab, Vincristine Sulfate, Vorinostat
- Drug · Other · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2027
- U.S. locations
- 190
- States / cities
- Mobile, Alabama • Tucson, Arizona • Fort Smith, Arkansas + 132 more
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm
- Interventions
- trivalent influenza vaccine, Immunoenzyme technique, Laboratory biomarker analysis
- Biological · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 459 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2013
- U.S. locations
- 2
- States / cities
- Duarte, California • Pasadena, California
- Conditions
- Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma
- Interventions
- Idelalisib
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 2
- States / cities
- Palo Alto, California • New York, New York
- Conditions
- Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
- Interventions
- Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Prophylactic Cranial Irradiation, Thioguanine, Vincristine Sulfate
- Drug · Other · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2021
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Long Beach, California • Los Angeles, California + 20 more
- Conditions
- Diffuse Large B Cell Lymphoma, Multiple Myeloma
- Interventions
- PointCheck
- Diagnostic Test
- Lead sponsor
- Leuko Labs, Inc.
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 210 participants
- Timeline
- 2025 – 2027
- U.S. locations
- 5
- States / cities
- Honolulu, Hawaii • Louisville, Kentucky • Boston, Massachusetts + 2 more
- Conditions
- Cutaneous T Cell Lymphoma, Mycosis Fungoides
- Interventions
- UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis, THERAKOS® CELLEX photopheresis system
- Drug · Device
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Epstein-Barr Virus-Associated Lymphoma, Lymphoproliferative Disorders
- Interventions
- VRx-3996 and valganciclovir
- Combination Product
- Lead sponsor
- Viracta Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 22
- States / cities
- Los Angeles, California • Orange, California • Aurora, Colorado + 15 more
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia
- Interventions
- therapeutic autologous lymphocytes, cyclophosphamide, aldesleukin, polymerase chain reaction, gene rearrangement analysis, lymph node biopsy, genetically engineered lymphocyte therapy, bone marrow aspiration, flow cytometry, laboratory biomarker analysis, enzyme-linked immunosorbent assay
- Biological · Drug · Genetic + 2 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
- Interventions
- Pirtobrutinib
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 787 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 18
- States / cities
- Jacksonville, Florida • Miami, Florida • Sarasota, Florida + 15 more
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- aldesleukin, bryostatin 1
- Biological · Drug
- Lead sponsor
- National Institute on Aging (NIA)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Follicular Lymphoma, Lymphoma
- Interventions
- Mosunetuzumab, Zanubrutinib
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 9
- States / cities
- Washington D.C., District of Columbia • Basking Ridge, New Jersey • Hackensack, New Jersey + 6 more
- Conditions
- Lymphoma
- Interventions
- rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, yttrium Y 90 ibritumomab tiuxetan
- Biological · Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 81
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 58 more
- Conditions
- Hodgkin Lymphoma
- Interventions
- CD19 RNA redirected autologous T-cells (RNA CART19 cells)
- Biological
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 24 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, B-cell Adult Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Hairy Cell Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, T-cell Adult Acute Lymphoblastic Leukemia, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Waldenström Macroglobulinemia
- Interventions
- Akt inhibitor MK2206, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Chronic Lymphocytic Leukemia, B-Cell Lymphoma
- Interventions
- DTRMWXHS-12, DTRM-505, DTRM-555
- Drug
- Lead sponsor
- Zhejiang DTRM Biopharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • New Haven, Connecticut • Jacksonville, Florida + 3 more
- Conditions
- Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome
- Interventions
- IPH4102
- Biological
- Lead sponsor
- Innate Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orange, California + 12 more
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- gallium nitrate
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2004
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • Milwaukee, Wisconsin
- Conditions
- Asthma
- Interventions
- NC100182 Hyperpolarized 3He
- Other
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 6 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2021
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Peripheral T-cell Lymphoma
- Interventions
- Belinostat, CHOP
- Drug
- Lead sponsor
- Acrotech Biopharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 8
- States / cities
- New Haven, Connecticut • Athens, Georgia • Rochester, Minnesota + 5 more
- Conditions
- Neoplasms, Non-Hodgkin Lymphoma, Hodgkin Disease
- Interventions
- TPI 287 Injection
- Drug
- Lead sponsor
- Cortice Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 4
- States / cities
- Tucson, Arizona • Denver, Colorado • Washington D.C., District of Columbia + 1 more